ArticleFrontiers in pharmacology2022
Effects of
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Jiuwei Xiaozhi Decoction Alleviates High-Fat Diet-Induced MASLD by Suppressing Hepatic SREBP2-Driven Cholesterogenesis and Restoring PPARα-Mediated Fatty Acid Oxidation.Chemical biology & drug design · 2026Article
- Hu Gan Tang Ameliorates Lipid Deposition of Metabolic-Associated Fatty Liver Disease by Promoting Autophagy Through the AMPK/mTOR Pathway.Chemistry & biodiversity · 2026Article
- Unraveling the ameliorative effects of Ling-Gui-Zhu-Gan decoction on MASLD: an integrative gut microbiota and lipidomic study.Frontiers in microbiology · 2026Article
- Dehydrotrametenolic acid methyl ester, a triterpenoid of Poria cocos, alleviates non-alcoholic steatohepatitis by suppressing NLRP3 inflammasome activation via targeting Caspase-1 in mice.Acta pharmacologica Sinica · 2025Article
- Huangqi fuling decoction inhibits the invasion and metastasis of gastric cancer via the TNF signaling pathway.Scientific reports · 2025Article
- Article
- Xingxiao Pill Suppressed the Progression of Non-Small Cell Lung Cancer by Targeting SREBP1/FASN-Induced Fatty Acid Biosynthesis via PI3K/AKT/mTOR Signaling Pathway.Cancer management and research · 2025Article
- The Active Components of Traditional Chinese Medicines Regulate the Multi-Target Signaling Pathways of Metabolic Dysfunction-Associated Fatty Liver Disease.Drug design, development and therapy · 2025Review
- Replacement of fish meal with full fatHeliyon · 2024Article
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Article
- The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications.Acta pharmaceutica Sinica. B · 2024Review
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.Journal of natural medicines · 2024Article
- The Effects ofFoods (Basel, Switzerland) · 2024Article
- Effect ofInternational journal of molecular sciences · 2024Article
- TCMNPAS: a comprehensive analysis platform integrating network formulaology and network pharmacology for exploring traditional Chinese medicine.Chinese medicine · 2024Article
- Wulingsan Alleviates MAFLD by Activating Autophagy via Regulating the AMPK/mTOR/ULK1 Signaling Pathway.Canadian journal of gastroenterology & hepatology · 2024Article
- Ling-gui-zhu-gan promotes adipocytes browning via targeting the miR-27b/PRDM16 pathway in 3T3-L1 cells.Frontiers in pharmacology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the increase in the global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD), no approved drug currently exists for the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.